BiotechTube

CS8635 20/5/12.5mg and placebo + Olmetec® Plus 20/12.5mg and placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Essential Hypertension

Conditions

Essential Hypertension

Trial Timeline

Apr 1, 2013 → Aug 1, 2014

NCT ID
NCT01838850

About CS8635 20/5/12.5mg and placebo + Olmetec® Plus 20/12.5mg and placebo

CS8635 20/5/12.5mg and placebo + Olmetec® Plus 20/12.5mg and placebo is a phase 3 stage product being developed by Daiichi Sankyo for Essential Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT01838850. Target conditions include Essential Hypertension.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01838850Phase 3Completed

Competing Products

20 competing products in Essential Hypertension

See all competitors
ProductCompanyStageHype Score
L04RD1 + L04TD3CelltrionPhase 1
33
Azilsartan MedoxomilCelltrionPre-clinical
23
AZM X mg + AML Y mg + AZM X mg + AML Y' mg + AZM X' mg + AML Y mg + AZM X' mg + AML Y' mg + AZM X mg + AZM X' mg + AML Y mg + AML Y' mgCelltrionPhase 3
77
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved
85
Anagre Cap.YuhanApproved
85
Telmisartan/Amlodipine/Chlorthalidone(Truset)YuhanPre-clinical
23
olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo + olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets + olmesartan medoxomil/hydrochlorothiazide tablets + olmesartan medoxomil/hydrochlorothiazide tabletsDaiichi SankyoPhase 3
77
olmesartan medoxomil + hydrochlorothiazide, if necessary + losartan + hydrochlorothiazide, if necessaryDaiichi SankyoPhase 3
77
CS-3150 + olmesartan medoxomilDaiichi SankyoPre-clinical
23
olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo + Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo + olmesartan medoxomil + amlodipine + hydroclororthiazide + olmesartan medoxomil + amlodipine + hydroclororthiazide + olmesartan medoxomil + amlodipine + hydroclororthiazide + olmesartan medoxomil + amlodipine + olmesartan medoxomil + amlodipine + olmesartan medoxomil + amlodipineDaiichi SankyoPhase 3
77
Olmesartan medoxomil + Atenolol + Hydrochlorothiazide + olmesartan medoxomil + atenololDaiichi SankyoPhase 3
77
olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
85
CS-3150 + EplerenoneDaiichi SankyoPhase 3
77
olmesartan medoxomil + losartan potassiumDaiichi SankyoPhase 3
77
Olmesartan medoxomil 40 mg - Amlodipine 10 mg + Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg + Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg + OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg + OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg + OLM 40mg-AML 10mg-Hydrochlorothiazide 25mgDaiichi SankyoPhase 3
77
olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
85
Olmesartan medoxomil + Losartan + Furosemide oral tabletsDaiichi SankyoPhase 3
77
olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets + olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mgDaiichi SankyoPhase 3
77
olmesartan medoxomil + amlodipineDaiichi SankyoPhase 3
77
olmesartan medoxomil + amlodipine + hydrochlorothiazideDaiichi SankyoPhase 3
77

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85